Fuel reforming device
AssigneeUniversity of Zurich
InventorMarc Donath
Life of this patent
Estimating the term…
Abstract
Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
Claims14
Use of an Interleukin 1 receptor antagonist (IL-1Ra) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal.
The use according to any of the preceding claims, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra).
Use of pyrrolidinedithiocarbamate (PDTC) for the preparation of a medicament for the treatment or prophylaxis of type 2 diabetes in a mammal.
A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of an Interleukin I receptor antagonist (IL-1Ra).
The method according to 9, wherein the Interleukin 1 receptor antagonist (IL-1Ra) is a recombinant human protein (rhIL-1Ra).
A method of treating or prophylactically suppressing type 2 diabetes, the method comprising administering to a mammal in need thereof a sufficient amount of pyrrolidinedithiocarbamate (PDTC).
Dependencies are inferred from the claim text.